Méndez Rosa, Ruiz-Cabello Francisco, Rodríguez Teresa, Del Campo Ana, Paschen Annette, Schadendorf Dirk, Garrido Federico
Servicio de Análisis Clínicos e Inmunología, Hospital Universitario Virgen de las Nueves, Avda Fuerzas Armadas s/n, 18014, Granada, Spain.
Cancer Immunol Immunother. 2007 Jan;56(1):88-94. doi: 10.1007/s00262-006-0166-2. Epub 2006 Apr 19.
The cytotoxic activity of T cells selects the outgrowth of tumor cells that escape from immune surveillance by different strategies. The different mechanisms that interfere with immune recognition and limit vaccination efficiency are still poorly understood. We analysed six cell lines established from different metastases of melanoma patient UKRV-Mel-20 for specific characteristics known to have an impact on the tumor-T cell interaction: (1) alterations in the HLA class I phenotype, (2) expression of Fas/CD95, and (3) expression of specific cytokines and chemokines. One of the cell lines, UKRV-Mel-20f, exhibited an HLA class I haplotype loss and just this cell line was also characterised by the expression of Fas/CD95 and of relatively high levels of proinflammatory chemokines suggesting that the cytotoxic activity of tumor-infiltrating T cells might have selected the outgrowth of this tumor cell variant. All other cell lines analysed showed no alterations in HLA class I expression, but, in contrast to UKRV-Mel-20f, expressed much lower levels of Fas/CD95 and of proinflammatory chemokines and some of them produced high levels of immunosuppressive TGF-beta1. These results suggest that in patient UKRV-Mel-20, tumor cells interfere with T cell recognition by different strategies which might partially explain why this patient did not have a clinical response to an autologous tumor cell vaccine.
T细胞的细胞毒性活性会选择那些通过不同策略逃避免疫监视的肿瘤细胞生长。不同的干扰免疫识别并限制疫苗接种效率的机制仍未得到充分理解。我们分析了从黑色素瘤患者Ukrv-Mel-20的不同转移灶建立的六个细胞系,以确定已知对肿瘤-T细胞相互作用有影响的特定特征:(1)HLA I类表型的改变,(2)Fas/CD95的表达,以及(3)特定细胞因子和趋化因子的表达。其中一个细胞系Ukrv-Mel-20f表现出HLA I类单倍型缺失,而恰恰是这个细胞系还具有Fas/CD95表达以及相对高水平的促炎趋化因子表达的特征,这表明肿瘤浸润T细胞的细胞毒性活性可能选择了这种肿瘤细胞变体的生长。分析的所有其他细胞系在HLA I类表达上均未显示改变,但与Ukrv-Mel-20f相反,它们表达的Fas/CD95和促炎趋化因子水平要低得多,并且其中一些产生高水平的免疫抑制性TGF-β1。这些结果表明,在患者Ukrv-Mel-20中,肿瘤细胞通过不同策略干扰T细胞识别,这可能部分解释了为什么该患者对自体肿瘤细胞疫苗没有临床反应。